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Abstract
In classic Hodgkin lymphoma (HL) the malignant mononuclear Hodgkin (H) and multinuclear Reed-Sternberg (RS)
cells are characterized by a distinct three-dimensional nuclear telomere organization with shortening of the telomere
length and the formation of telomeric aggregates. We asked if the severity of these telomere changes correlates with
the clinical behavior of the disease. We retrospectively evaluated three-dimensional telomere organization by quanti-
tative fluorescent in situ hybridization (Q-FISH) of diagnostic biopsies from 16 patients whowere good responders and
compared them with 16 diagnostic biopsies of 10 patients with refractory or relapsing HL (eight initial biopsies, four
confirming progressions, and four confirming relapses). The H cells from patients with refractory/relapsing disease
contained a significantly higher percentage of very small telomeres (P = .027) and telomere aggregates (P = .032)
compared with H cells of patients entering rapid remission. These differences were even more significant (P = .002
and P = .013, respectively) when comparing the eight initial diagnostic biopsies of refractory/relapsing HL with
diagnostic biopsies of eight patients with ongoing long-lasting remission (mean of 47 months). This specific three-
dimensional telomere Q-FISH signature identifies these highly aggressive mononuclear H cells at the first diagnostic
biopsy and thus may offer a new molecular marker to optimize initial treatment.
Translational Oncology (2012) 5, 269–277
Introduction
Telomeres are the nucleoprotein complexes at the ends of chromosomes.
Telomeric DNA consists of multiple double-stranded TTAGGG
repeats and ends in a single-stranded overhang of the G-rich 3′ strand
[1]. Furthermore, a number of specific proteins, either binding telomeric
DNA directly or being associated with telomeric chromatin, called
shelterin complex, are found on telomeres [2,3]. Many cancer cells dis-
play chromosomal aberrations that are the direct result of telomere dys-
function [4,5] and the three-dimensional organization of telomeres is
altered in cancer cells [6,7].
This basic finding led to an advanced understanding of genetic
changes in early cancer cells and proved that telomere organization
is key to genome stability versus instability [8,9]. We have shown
that each nucleus has a specific three-dimensional telomeric signature
that defines it as normal or aberrant. Four criteria define this differ-
ence; 1) nuclear telomere distribution, 2) the presence/absence of
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telomere aggregate(s), 3) telomere numbers per cell, and 4) telomere
sizes [10,11].
The binuclear or multinuclear Reed-Sternberg cells (RS cells), the
diagnostic element of Hodgkin lymphoma (HL), derive from mono-
nuclear precursors called Hodgkin (H) cells, through endoreduplica-
tion and have a limited capacity to further divide [12–14]. H cells
originate from germinal center B cells [15], and small circulating clono-
typic B cells, putative precursors of H cells, have been identified by flow
cytometry [16]. H and RS cells show high telomerase activity [17,18]
and express abundant telomerase RNA [19].
Using a three-dimensional quantitative fluorescent in situ hybrid-
ization (Q-FISH) technique to visualize telomeres in cultured cells
and biopsies [8], we recently characterized the transition from mono-
nuclear H to multinuclear RS cells at the molecular level [20–22].
We demonstrated that RS cells are true end-stage tumor cells in both
classic Epstein-Barr virus (EBV)–negative and EBV-positive HL.
The number of nuclei in these RS cells correlates closely with the
three-dimensional organization of telomeres and further nuclear divi-
sions are hampered by sustained telomere shortening or loss and telo-
mere aggregation. The increase in very small telomeres and aggregates
in these RS cells compared with their mononuclear precursor H cells is
highly significant (P < .01). Such RS cells contain telomere/DNA–poor
“ghost” nuclei and giant “zebra” chromosomes including up to seven
different chromosomal partners as revealed by spectral karyotyping
(SKY). These molecular changes are the result of multiple breakage-
bridge-fusion (BBF) cycles [22].
With the ability of three-dimensional nuclear telomere analysis to
be performed on paraffin-embedded tissue blocks to specifically
address the nuclear structure in the minor population of cells in HL
that are the malignant component (H and RS cells), we had the tool
to now ask whether there were differences in the H and RS cells of
patients with primary refractory or relapsing HL compared with those
of good responders. In this study, we analyzed 16 diagnostic lymph
node biopsies from patients entering rapid remission and compared
them to 16 lymph node biopsies from 10 patients who went on to have
relapse or refractory disease. Our results show significant differences in
three-dimensional telomere dynamics of relapsing/progressing disease.
Materials and Methods
Study Design
From January 2006 to January 2011, patients diagnosed by lymph
node biopsy for HL or closely related diseases at the Université de
Sherbrooke were enrolled in the trial to evaluate telomere structure
by three-dimensional telomere Q-FISH analysis performed on archived
histology slides of diagnostic biopsies. This tumor biology study did not
affect patient management. Forty-two patients entered the study (most
of them prospectively), 33 had histologic diagnosis (lymph node) of
classic HL, 4 had lymphocyte-predominant nodular HL, 3 had
EBV-associated angioimmunoblastic T-cell lymphoma (LMP1+),
1 had T-cell anaplastic large cell lymphoma ALK+, and 1 had EBV-
positive large B-cell lymphoma. Among the patients with HL, four were
referred from other centers (three with relapsing/progressing disease).
Clinical Response Definition
Remission from HL was defined by fluorodeoxyglucose (FDG)
positron emission tomography–computed tomography (PET/CT)
scan (and bone marrow biopsy for patients with initial bone marrow
involvement). The activity of involved sites had to disappear com-
pletely by follow-up FDG PET/CT scan when compared with the
FDG PET/CT scan performed at diagnostic workup. In patients with
initial bone marrow involvement, a follow-up bone marrow biopsy
had to get cleared of CD30+ tumor cells. Follow-up FDG PET/CT
scan was performed at the treating physician’s discretion but at least
after the fourth cycle of chemotherapy. Patients in remission had at
least two additional FDG PET/CT scans within the first year after
completion of treatment.
Ethics
The study design has been approved by the institutional ethics
committee of the Université de Sherbrooke and the institutional review
board of the University of Manitoba. Informed consent of each patient
has been obtained, and the investigations have been conducted accord-
ing to the Declaration of Helsinki.
Tissue Slides
Serial sections (5 μm thick) from archived formalin-fixed paraffin-
embedded tissue from every lymph node biopsy diagnostic for classic
Hodgkin’s disease (initial diagnosis, diagnosis of relapse, diagnosis of
progression) were deparaffinized two times for 15 minutes at room
temperature in xylene and rehydrated in reverse-graded series of
ethanol (incubations are 100%, 75%, 70%, and 50% for 10 minutes
each). The slides were then dipped briefly in ddH2O and then trans-
ferred into phosphate-buffered saline and used for hematoxylin-eosin
staining (serial section no. 1), immunostaining (anti-CD30, serial
section no. 2; anti-LMP1, serial section no. 3), and Q-FISH (serial
section no. 4).
Identification of LMP1 Expressing H and RS Cells on
Serial Sections with Combined Three-dimensional
DAPI/Cy-3 Telomere Q-FISH Nuclear Staining
On serial section no. 3, lymph node regions with LMP1-expressing
H and RS cells were identified at a magnification of 200× and indi-
vidual cells were further confirmed at a magnification of 630×. Sub-
sequently, on serial section no. 4, the corresponding region was
identified at a magnification of 200×, and the corresponding H and
RS cells (hence, LMP1-expressing) were further analyzed for three-
dimensional nuclear telomere organization at a magnification of 630×.
Immunohistochemistry
Immunostaining was performed by standard indirect immuno-
peroxidase technique using primary monoclonal mouse antibodies anti-
CD30 (Ber-H2) and anti-LMP1 (clones CS1-CS4) from DAKO
(Glostrup, Denmark) at a dilution of 1:40 and 1:50, respectively.
Photomicrographs were performed by using a Zeiss Axioskop 2 micro-
scope (Carl Zeiss Canada, Toronto, Canada) with a Polaroid C11806TV
camera and Polaroid DMC2 v2.01 software (Kodak, Toronto, Canada).
Telomere Q-FISH
The telomere FISH protocol was performed [6,8] by using Cy3-
labeled peptide nucleic acid probes (DAKO). Imaging of interphases
after telomere FISH was performed by using Zeiss AxioImager Z1
with a cooled AxioCam HR B&W, DAPI, Cy3 filters in combination
with a Planapo 63×/1.4 oil objective lens. Images were acquired by
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using AxioVision 4.6 and 4.8 (Zeiss) in multichannel mode followed by
constraint iterative deconvolution as specified in the next paragraphs.
Three-dimensional Image Acquisition
At least 30 H-cell interphase nuclei and 30 RS-cell interphase
polycaria were analyzed in each lymph node slide. AxioVision 4.6
and 4.8 with deconvolution module and rendering module were
used. For every fluorochrome, the three-dimensional image consists
of a stack of 40 images with a sampling distance of 200 nm along
the z and 107 nm in the x and y direction. The constraint iterative
algorithm option was used for deconvolution [23].
Three-dimensional Image Analysis for Telomeres
Telomere measurements were done with TeloView [6,24]. By
choosing a simple threshold for the telomeres, a binary image is found.
On the basis of this threshold, the center of gravity of intensities is
calculated for every object, resulting in a set of coordinates (x, y, z)
denoted by crosses on the screen. The integrated intensity of each telo-
mere is calculated because it is proportional to the telomere size [25].
a) Segmental nuclear volume: Nuclear volume within one 5-μm-
thin nuclear section of H cells or RS cells is calculated ac-
cording to the three-dimensional nuclear DAPI staining as
previously described [26]. Contrary to whole cell preparations
(cells or cell lines), where the nuclei can be visualized with their
entire volumes and z-stack analysis along the z direction over
15 μm allows to calculate the entire nuclear volume, in tissue
sections, analysis of the nuclear volume is limited to 5-μm nuclear
segments (as used as a standard for histopathologic diagnosis)
along the z direction. Deparaffinized tissue slides of 10 and
15 μm thickness are technically unsatisfactory for Q-FISH analy-
sis. Thus, the segmental nuclear volume represents approximately
30% to 50% of the total nuclear volume of H cells (with a nuclear
diameter of approximately 10-15 μm) and approximately 15% to
25% of the total nuclear volume of RS cells (diameter of two up
to several nuclei measures approximately 20-40 μm).
b) Segmental telomere number: Segmental telomere number is the
sum of all very small, small, midsized, and large telomeres and
aggregates identified within one 5-μm-thin nuclear section of an
H cell or RS cell.
c) Segmental telomere intensity: Segmental telomere intensity is the
sum of intensities of all very small, small, midsized, and large
telomeres and aggregates identified within one 5-μm-thin nuclear
section of an H cell or RS cell (viz., ∑ 2 × 15,000 units > ∑ 7 ×
4000 units).
d) Mean telomere intensity: Mean telomere relative fluorescent in-
tensity (size) of all telomeres within a given segmental volume.
e) Telomere size: Telomeres with a relative fluorescent intensity
(x axis) ranging from 0 to 5000 units are classified as very small,
with an intensity ranging from 5000 to 15,000 units as small, with
an intensity from 15,000 to 30,000 units as midsized, and with
an intensity greater than 30,000 units as large [21].
f ) Telomere aggregates: Telomere aggregates are defined as clusters
of telomeres that are found in close association and cannot be
further resolved as separate entities at an optical resolution limit
of 200 nm [9].
Statistical Analysis
In each case of classic HL, at least 30 H cells and 30 RS cells have
to be analyzed by three-dimensional telomere Q-FISH. If there were
fewer than 30 H and RS cells present on a diagnostic slide, it was
insufficient for reliable statistical analysis, and the slide was not
included. Unequivocal statistical analysis could be performed on
32 diagnostic biopsies of 26 patients with diagnosis of classic HL
(in patients with relapsing/progressing disease, second and third biop-
sies diagnostic for relapse or progression were analyzed; Table 1B ). For
each case, normally distributed parameters are compared between the
two types of cells using nested analysis of variance or two-way analysis
of variance. Multiple comparisons using the least square means tests
followed where interaction effects between two factors were found to
be significant. Other parameters that were not normally distributed
were compared using a nonparametric Wilcoxon rank sum test. Sig-
nificance level were set at P = .05. Analyses were done using SAS
v9.1 programs (SAS Institute Inc, Cary, NC).
Results
Clinical Data Including Outcome
A total of 32 diagnostic biopsies were adequate for statistical anal-
ysis; 16 biopsies from 16 patients belonged to patients entering rapid
remission, belong to group A, (remission documented after fourth
cycle of chemotherapy at the latest), and 16 diagnostic biopsies (eight
initial biopsies including two patients never entering remission, four
documenting relapse and four disease progression) from 10 patients
belonged to group B. The clinical data including treatment modalities,
international prognostic score (IPS), and outcome of both groups are
shown on Table 1, A and B, respectively. The groups were similar for
age and IPS score. Stage IV disease was more frequent in patients of
group B (3 vs 1).
Three-dimensional Telomere Q-FISH Group A
The nuclear telomere organization of patients entering rapid re-
mission is shown on Table 2A. Compared with mononuclear H-cell
nuclei, RS-cell nuclei have a significantly larger volume and are char-
acterized by a significant increase in the number of very small telo-
meres and aggregates (P < .01), as defined in Materials and Methods,
whereas the total telomere mass (segmental telomere intensity) was
nearly unchanged (P = .395). As a result, the mean telomere intensity
in RS cells is much lower compared with that in H cells (P < .01).
When the total telomere mass is normalized to a virtual nuclear vol-
ume of 1000 μm3, RS cells show a significant decrease in the total
telomere mass (P < .01) compared with H cells underscoring the
shortening and loss of telomeres associated with the transition from
H to RS cells, confirming our earlier observations [20,21].
Three-dimensional Telomere Q-FISH Group B
The nuclear telomere organization in patients with progressing or
relapsing disease is shown on Table 2B. Again, compared with
mononuclear H-cell nuclei, RS-cell nuclei have a significantly larger
volume and are characterized by a significant increase in number of
very small telomeres and aggregates (P < .01) but also by a significant
increase (P < .01) of the total telomere mass (segmental telomere inten-
sity). However, when the total telomere mass is normalized to a virtual
nuclear volume of 1000 μm3, this increase in the total telomere mass
is no longer identifiable (P = .493), with a remaining still-significant
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decrease of the mean telomere intensity (P = .014). Most importantly,
these differences between RS and H cells—although analogous to those
identified within the rapid remission group A—do occur at a much
advanced level. For instance, the number of very small telomere
increases between H and RS cells in group B from 68.8% to 81.8%
(Table 2B ), whereas a similar increase, but at a much lower level, from
48.0% to 72.4%, is identified in group A (Table 2A). In analogy, the
number of telomere aggregates increases between H and RS cells from
3.1 to 4.9 in group B but from 1.9 to 3.4 in group A, respectively.
Thus, in relapsing and refractory cases, the characteristics of three-
dimensional nuclear telomere abnormalities are much more pro-
nounced with a higher observed number of very small telomeres and
telomere aggregates as well as a decreased mean telomere intensity (Fig-
ure 1). This process is dynamic and it was noted to worsen with
advanced disease stage as seen in TeloView analysis of a second refrac-
tory relapse (Figure 2).
Comparison of the Three-dimensional Telomere Characteristics of
Groups A and B
Most importantly, the mononuclear H cells of progressing/relaps-
ing cases, still capable of completing mitosis resulting in two mono-
nuclear daughter H cells, have already telomere characteristics
identified in RS cells of the rapid remission cases as shown in the
right track of Table 3. These H cells of group B differ from the
RS cells of group A in terms of the expected difference in nuclear
volume (391 vs 666 μm3), whereas the number of aggregates per cell
(3.1 vs 3.4) and the percentage of very small telomere (68.8% vs
72.4%) are very similar; however, both, aggregates and a very small
telomere of H cells of group B, have significantly increased compared
with those of H cells of group A (P = .032 and P = .027, respectively;
first track of Table 3). These differences are even more significant for
very small telomeres (P = .002) and for aggregates (P = .013) when
comparing the eight initial biopsies of refractory/relapsing HL (biop-
sies 17a, 19a, 20a, 21a, 22a, 23a, 25a, and 26a) with the diagnostic
biopsies eight patients (biopsies 1-7.12) entering rapid and still
ongoing sustained remission (27-70 months; mean of 47 months).
Notably, these three-dimensional telomere dynamics were identified
before identical ABVD chemotherapy (except case 23a) in both
groups and, consequently, the different clinical course independent
of initial treatment modality. For the H cells of the refractory/
relapsing cases, this is consistent with multiple completed rounds
of cellular division (i.e., repeated telomere shortening) that are
Table 1. Clinical Data: Rapid Remission Group A (A) and Progression/Relapse Group B (B).
(A) Rapid Remission Group A
Case No. Sex Age (years) HL Type Stage (Costwolds) IPS Remission (After Cycle) Remission Duration (months)
1 F 57 MC LMP1+ IIIA 1 4 × ABVD 69
2 M 24 MC LMP1+ IIIB 1 1 × ABVD 27
3 M 42 MC IA 1 2 × ABVD 28
4 M 19 NS IVA 2 2 × ABVD 35
5 F 28 NS LMP1+ IIA 0 4 × ABVD 50
6 M 27 NS IIIs A 1 3 × ABVD 34
7 M 34 NS IIIB 2 4 × ABVD 70
8 M 30 NS LMP1+ IIA 1 2 × ABVD 17
9 M 46 NS LMP1+ IIA 1 1 × ABVD 16
10 F 35 NS IIIs B 1 1 × CVPP-AO 17
11 M 17 NS IIB bulky 1 4 × DBVE-PC + IFRT 42
12 M 71 MC LMP1+ IIIB 4 4 × ABVD 62
13 M 23 SN IIIB 4 4 × ABVD 9
14 M 58 MC LMP1+ IIIB 2 2 × ABVD 6
15 M 40 NS IIB bulky 2 4 × ABVD + IFRT 6
16 F 73 NS IIIB 5 4 × ABVD 23
(B) Progression/Relapse Group B
Case No. Sex Age (years) HL-type Stage IPS Progression (prog)/Remission (rem)/Relapse (rel)/Outcome
17a F 77 NS LMP1+ IIIB 4 4 × ABVD → prog
b NS LMP1+ IIIB 2 2 × R-Gem → prog, → death after 5 months
18b F 41 NS IIA bulky 1 3 × ESHAP, BEAC + auto BMT, → prog, → IFRT, → prog, death after 6 months
19a M 61 NS IIIB 1 6 × ABVD → rem, → rel after 10 months
b* NS IIA 2 2 × ESHAP, BEAM + auto BMT, → prog, 2 × R-Gem, → prog
20a* M 38 NS IVB s 3 6 × ABVD → rem, → rel after 60 months
b MC IVB 2 2 × ESHAP, BEAM + auto BMT, → rem, → rel after 48 months
c MC IIIB 4 4 × ICE, 2 × DHP → prog, → death after 9 months
21a M 21 NS IIIB 1 4 × ABVD → prog
b NS IIA 2 2 × ESHAP, BEAM + auto BMT, → prog, 2 × ICE, → prog, 2 × GDP, → prog, death after 3 months
22a M 49 NS IIIB 2 6 × ABVD → rem, → rel after 35 months
b NS IVB 2 3 × ESHAP → prog → death after seven months
23a F 14 NS IVA 0 4 × DBVE-PC + IFRT → rem → rel after four****months, auto BMT → in rem for 24 months
24b M 33 NS synctial IIB 1 3 × ESHAP → prog, 3 × ICE → prog → death after 2 months
25a M 48 NS IVB 6 6 × ABVD → rem, → rel after 5 months, 2 × ESHAP, BEAM + auto BMT, → in rem for 7 months
26a M 28 NS IIB 1 4 × ABVD → prog, 2 × ESHAP, BEAM + auto BMT, → in rem for 7 months
ABVD indicates adriamycin, bleomycin, vinblastine, dacarbazine; BEAC, carmustine, etoposide, cytarabine, cyclophosphamide; BEAM, carmustine, etoposide, cytarabine, melphalan; CVPP-AO,
cyclophosphamide, vinblastine, procarbazine, prednisone/adriamycin, oncovin; DBVE-PC, doxorubicin, bleomycin, vinblastine, etoposide/prednisone, cyclophosphamide; ESHAP, etoposide, cytarabine,
cisplatin, methylprednisolone; GDP, gemcitabine, dexamethasone, cisplatin; ICE, ifosphamide, carboplatin, etoposide; IFRT, involved field radiation therapy; IPS, international prognostic score; MC, mixed
cellularity classic HL; NS, nodular sclerosis classic HL; R-Gem, rituxan, gemcitabine.
*Biopsies with only RS cells statistically analyzed because the number of H cells in these biopsies was fewer than 30.
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completed with intact nuclear and cytoplasm segregation indicating
primary aggressive disease. This telomere profile contrasts with that
one of rapid remission cases (Figure 3, A and B). Importantly, the
mean segmental telomere intensity (mean total telomere mass) is
unchanged between H cells of group B (162,215 units) and RS cells
of group A (167,241 units) as well as the mean segmental telomere
number (31.0 vs 32.3). Thus, the mononuclear H cells of refractory/
relapsing cases behave in their three-dimensional nuclear telomere
signature like end-stage RS cells of the remission group A without being
it (Figure 4).
Figure 1. Three-dimensional nuclear organization of telomeres (red) and total nuclear DNA (blue) in RS cells of relapsing HL. Trinuclear
RS cell (biopsy 20b) showing unequal nuclear distribution of mainly very small telomere when compared with surrounding lymphocytes,
which contain midsized and large telomere. Small and very small telomere are clustered in the upper nucleus (1) of the RS cell whereas
the left (2) and lower right nucleus (3) behave like “ghost” elements with only few very small telomere. Inset highlights clustering and
very small telomere in the RS cell compared with adjacent lymphocytes.
Table 2. Three-dimensional Telomere Characteristics of RS Cells and H Cells of 16 (A; Rapid Remission Group A) and 14 Diagnostic Biopsies (B; Progression/Relapse Group B).
(A) Rapid Remission Group A: Statistics Including Seven LMP1–Expressing Cases
Parameter RS cells (n = 510; 223 LMP1+) H cells (n = 524; 235 LMP1+) P
Segmental nuclear volume 666 μm3 (422)* 366 μm3 (201) <.01
Segmental telomere number 32.3 (23.1) 20.9 (15.8) <.01
Segmental telomere intensity 162,215 units (148,233) 154,824 units (182,473) NS
Mean telomere intensity 5425 units (3362) 7682 units (4496) <.01
Very small telomere (0-5000 U) 72.4% (15.2) 48.0% (18.4) <.01
Segmental telomere aggregates 3.4 (3.3) 1.9 (2.3) <.01
(B) Progression/Relapse Group B: Statistics Including Two LMP1–Expressing Biopsies
Parameter RS cells (n = 467; 65 LMP1+) H cells (n = 473; 72 LMP1+) P
Segmental nuclear volume 718 μm3 (446)* 391 μm3 (193) <.01
Segmental telomere number 44.0 (33.3) 31.0 (21.7) <.01
Segmental telomere intensity 197,951 units (173,103) 167,241 units (125,141) <.01
Mean telomere intensity 5159 units (6968) 5986 units (3263) .014
Very small telomere (0-5000 u) 81.8% (15.5) 68.8% (15.1) <.01
Segmental telomere aggregates 4.9 (4.7) 3.1 (3.2) <.01
*Standard deviation.
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In summary, we conclude that H cells of relapsing/refractory HL
differ significantly from their counterparts of cases entering rapid and
persistent remission. A hallmark is the very high percentage of very
small telomeres and aggregates in these H cells.
Discussion
Over the past years, the success rate of modern treatment modalities
for HL has stagnated at approximately 80% to 85% [27]. In approx-
imately 20% of patients, the disease still progresses or relapses, despite
Figure 2. Quantitative assessment of three-dimensional telomeric profiles of RS cells in relapse and refractory disease by TeloView.
Three-dimensional Telomere dynamics in a biopsy (20b, same patient as in Figure 1) of late first relapse (after 6 years) and a biopsy
(20c) of a second relapse (4 years) after autologous bone marrow transplantation. Death occurred 9 months after this biopsy (20c) from
refractory disease. (A) Upper panel: The telomere signals (white crosses) are marked in three axes (x, y, z). Lower panel: The RS cell
contains a total of 74 mainly very small telomere and 6 aggregates (above the red line), and the mean telomere intensity is at 3864 units
and the segmental telomere intensity (total telomere mass) is at 347,732 units. (B) Upper panel: Qualitative assessment reveals no
differences to the telomere frequency observed in A. However, alignment according to intensity (lower panel) shows 90 mostly very
small telomere and 8 aggregates. Most importantly, the mean telomere intensity lowered to 2478 units and the segmental telomere
intensity (total telomere mass) to 247,780 units, demonstrating ongoing telomere shortening and loss.
Table 3. Rapid Remission Group A Versus Progression/Relapse Group B: Comparison of Three-dimensional Telomere Characteristics of RS Cells and H Cells (P ).
Comparison of Parameter H-A/H-B (16/14)* RS-A/RS-B (16//16) H-A/RS-B (16/16) H-B/RS-A (14/16)
Segmental nuclear volume NS NS <.01 (H-A < RS-B) <.01 (H-B < RS-A)
Segmental telomere number .015 (H-A < H-B) NS <.01 (H-A < RS-B) NS
Segmental telomere intensity NS NS NS NS
Mean telomere intensity .022 (H-A > H-B) NS <.01 (H-A > RS-B) NS
Very short telomere (<5000 units) .027 (H-A < H-B) NS <.01 (H-A < RS-B) NS
Segmental telomere aggregates .032 (H-A < H-B) NS <.01 (H-A < RS-B) NS
All parameters analyzed with the GLM procedure except telomeres less than 5000, this one was done with t test.
NS = P > .05.
H-A indicates Hodgkin cells group A; H-B, Hodgkin cells group B; RS-A, Reed-Sternberg cells group A; RS-B, Reed-Sternberg cells group B.
*Number of cases compared.
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multiple chemotherapies, radiation therapy, and autologous bone
marrow transplantation, demonstrating the need for a better molecular
knowledge of the biology of the malignant cells, mononuclear H, and
multinuclear RS cells [28,29]. It is most important to look for novel
treatment approaches for this group of patients [30] and to identify
such patients already at diagnosis before any therapy. Beside a high
IPS of advanced-stage disease [31], microenvironment factors such as
fibroblast activation and extracellular matrix remodeling [32], high
Figure 3. Typical telomere profiles associated with refractory disease (A) and rapid remission (B). Telomere distribution according to size in
mononuclear H (blue) and at least binuclear RS cells (red). Results are based on three-dimensional analysis of at least 30 H and 30 RS cells
in each biopsy. Frequency (y axis) and relative fluorescent intensity, that is, the size of telomeres (x axis) in a diagnostic 5-μm lymph node
section. (A) Female patient, 77 years old, nodular sclerosis subtype, LMP1-expressing stage IIIB, IPS 4, refractory disease, death after
11 months (case 17). In both, H and RS cells, there is a highly significant shift (P < .01) from midsized and small telomeres to very small
telomeres including “t-stumps” of 0 to 5000 relative fluorescence units. Importantly, already the mononuclear H cells exhibit a three-
dimensional telomere profile usually identified only in RS cells (arrow). (B) Male patient, 71 years old, mixed cellularity subtype, LMP1-
expressing stage IIIB, IPS 4, in remission for 62 months, documented after 4 × ABVD (case 12). In RS cells, the highly significant shift to
very small telomeres is still observed, whereas it is completely absent in H cells (arrow). Thus, H cells in aggressive disease do, contrary to
H cells in cases entering persistent remission, already contain multiple very small telomeres consistent with having passed multiple rounds
of mitosis without ending up in multinuclear end-stage RS cells. Notably, this is observed in cases with nearly identical clinical presentation.
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number of macrophages [33], and gains of chromosome 16p11.2-13.3
[34] are associated with unfavorable prognosis. On the other hand, the
expression of CD20 in H and RS cells [35] and the negative FDG
PET/CT scan results after two cycles of chemotherapy [36] are associ-
ated with a better prognosis. However, currently, there has not been a
cytologic/morphologic means to discern aggressive H and RS cells from
their chemotherapy-sensitive counterparts.
Here we show highly significant differences in the three-dimensional
telomere characteristics between H and RS cells of patients entering
rapid and sustained remission on first-line chemotherapy and those
of patients who have a relapsing or refractory disease course (Tables 2,
A and B ). H cells of refractory/relapsing cases already have a three-
dimensional telomere signature corresponding to that one of RS cells
in the remission group (Table 3 and Figure 4) without being end-
stage tumor cells. Importantly, when comparing the eight initial
diagnostic biopsies of the refractory/relapsing group with diagnostic
biopsies of eight patients entering rapid and still ongoing long re-
mission (mean of 47 months) before identical ABVD chemotherapy,
these differences are even more pronounced; H cells of aggressive HL
do contain much higher numbers of very small telomeres (P = .002)
and more aggregates (P = .013) than do H cells of diagnostic biopsies
entering long-lasting remission. H cells of refractory/relapsing cases—
although having passed through multiple rounds of mitotic division,
as shown by accumulation of very small telomeres and increase in
aggregates—are still capable to of further cell division and thus will
increase the tumor bulk.
Modeling the telomere abnormalities found in relapsing/refractory
stage HL are the Hodgkin cell lines L-428, HDLM-2, L-1236, and
U-HO1, all derived from advanced-stage HL, three of them refrac-
tory, where by far most cells (>90%) are mononuclear H cells [37–40].
These mononuclear H cells, despite having a high complexity of
chromosomal aberrations, are able to undergo mitotic division. Their
transition to multinuclear end-stage RS cells is associated with a further
increase in chromosomal complexity [22], formation of multiple aber-
rant mitotic spindles, telomere aggregates, and a further shortening of
telomere [20,41]. Such extremely small telomere, also called t-stumps
[42], and telomere aggregates are hallmarks of cancer cells [10].
Indeed, using innovative three-dimensional quantitative FISH
techniques for telomere dynamics and whole chromosome painting,
as well as spectral karyotyping (SKY), we have gained detailed molec-
ular insights into the transition of mononuclear H- to multinuclear
RS cells [20–22]. We identified RS cells of classic HL as true end-
stage tumor cells, characterized by abundant very small telomeres,
giant “zebra” chromosomes containing concatameric repeats from
two different, or parts originating from up to seven different chromo-
somes, and “ghost” nuclei poor or void of telomeres and chromosomes,
consistent with the hypothesis of multiple ongoing BBF cycles at the
origin of RS-cell generation. In line with this observation, three-
dimensional super resolution microscopy identified internuclear DNA
bridges between RS-cell nuclei and thus corroborated the generation of
RS cells as a result of multiple BBF cycles [22]. Thus, in refractory/
relapsing HL, the H cells have undergone already at diagnosis multiple
BBF cycles still allowing proper chromosomal segregation.
Our pathogenetic model is further supported by the emergence of
HL relapses with unrelated clonal rearrangements, as recently reported
[43]. This dynamic process of nuclear remodeling probably begins in
the few clonotypic circulating B cells identified recently by Jones et al.
in HL [16] or, in EBV-associated HL, even earlier in activated EBV-
infected tonsillar germinal center B cells that escape immunosurveillance
[44]. Indeed, telomere shortening and chromosomal instability in
peripheral blood lymphocytes of HL patients before any treatment have
been identified [45].
We have been able to identify a novel prognostic tool predictive of
poor biologic activity in HL—the three-dimensional nuclear telo-
mere structure. Studies are ongoing to confirm this observation in
an independent cohort of HL patients and to study a large-enough
cohort to evaluate whether this is an independent biomarker once stage,
subtype, age, and other known prognostic factors are analyzed. The
ability to study the nuclear structure of the malignant subpopulation
of HL has the potential of providing a major advance to the field of
HL management.
In summary, H and RS cells are characterized by a distinct three-
dimensional telomere nuclear organization. Three-dimensional telo-
mere signatures of mononuclear H cells in refractory/relapsing HL
are significantly different from those in HL rapidly entering sus-
tained remission. In refractory Hodgkin disease, the H cells show a
three-dimensional telomere fingerprint (significantly higher number
of very small telomeres and aggregates) nearly identical to that one
of RS cells of the remission group. These H cells appear to escape
standard chemotherapy but may be responding to novel therapeutic
approaches [30].
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Figure 4. Telomere distribution according to size in H and RS cells
in rapid remission and relapsing/refractory HL. The mean telomere
distributions (±SEM) in H and RS cells of 16 patient biopsies as-
sociated with rapid remission (group A) and 16 biopsies (8 initial
biopsies, 4 relapses, and 4 progressions) from 10 patients (group B)
are shown. Results are based on three-dimensional analysis of at
least 30 H and 30 RS cells in a diagnostic 5-μm-thin lymph node
section of each biopsy. Frequency (y axis) and relative fluorescent
intensity, that is, the size of telomeres (x axis) are shown. There is a
highly significant shift (P< .01) from small telomere (>5000 relative
fluorescence units) to very small telomere including “t-stumps” of
0 to 5000 relative fluorescence units in all four curves. However,
mononuclear H cells of aggressive disease have nearly as much
very small telomere (P = .374) as RS cells of cases entering rapid
and lasting remission indicating multiple rounds of mitotic division
without progression to end-stage RS cells.
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